Antipsychotic polypharmacy in outpatients at birch hill hospital: Incidence and adherence to guidelines

Journal of Clinical Pharmacology

Volumn 50, Issue 6, 2010, Pages 699-704

  Ranceva, Nadezda ^a   Ashraf, Wasim ^b   Odelola, Deji ^c  

^a WESTERN HEALTH AND SOCIAL CARE TRUST   (United Kingdom)

^b ROYAL BOLTON HOSPITAL   (United Kingdom)

^c Birch Hill Hospital   (United Kingdom)

Author keywords

Antipsychotics; Clinical pharmacology (CPH); Outpatients; Polypharmacy; Psychiatry (PSY)

Indexed keywords

ARIPIPRAZOLE; CHLORDIAZEPOXIDE; CLONAZEPAM; DIAZEPAM; FLUPENTIXOL DECANOATE; HYPNOTIC AGENT; NITRAZEPAM; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEDATIVE AGENT; ZOPICLONE;

ADULT; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MONOTHERAPY; OUTPATIENT CARE; POLYPHARMACY; PRACTICE GUIDELINE; PRESCRIPTION; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; CLINICAL AUDIT; ENGLAND; GUIDELINE ADHERENCE; HEALTH PLANNING GUIDELINES; HUMANS; HYPNOTICS AND SEDATIVES; INCIDENCE; MENTAL DISORDERS; PHYSICIAN'S PRACTICE PATTERNS; POLYPHARMACY; PRACTICE GUIDELINES AS TOPIC;

EID: 77953776998     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009350625     Document Type: Article

References (29)

1. Centorrino F., Eakin M., Bahk W-M., et al. Inpatient antipsychotic drug use in 1998, 1993, and 1989. Am J Psychiatry. 2002 ; 159: 1932-1935.
2. Ereshevsky L. Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic. J Clin Psychol. 1999 ; 60 (suppl 10). 20-30.
3. Procyshyn RM, Kennedy NB, Tse G., Thompson B. Antipsychotic polypharmacy: survey of discharge prescriptions from a tertiary care psychiatric institution. Can J Psychol. 2001 ; 46: 334-339.
4. Clark RE, Bartels SJ, Mellman TA, Peacock WJ Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr Bull. 2002 ; 28: 76-84.
5. Stahl SM Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials. J Clin Psychol. 1999 ; 60 (suppl 10). 31-41.
6. Leslie DL, Rosenheck RA Use of pharmacy data to assess quality of pharmacotherapy for schizophrenia in a national health care system: individual and facility predictors. Med Care. 2001 ; 39: 923-933.
7. Gilmer TP, Dolder CR, Folsom DP, Mastin W., Jeste DJ Antipsychotic polypharmacy trends among Medi-Cal beneficiaries with schizophrenia in San Diego County, 1999-2004. Psychiatr Services. 2007 ; 58: 1007-1010.
8. Ito H., Koyama A., Higuchi T. Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription. British J Psych. 2005 ; 187: 243-247.
9. Taylor D. Antipsychotic prescribing-time to review practise. Psychol Bull. 2002 ; 26: 401-402.
10. Lelliot P., Paton C., Harrington M., Konsolaki M., Sensky T., Okocha C. The influence of patient variables on polypharmacy and combined high-dose antipsychotic drugs prescribed for in-patients. Psychol Bull. 2002 ; 26: 411-414. (Pubitemid 35331237)
11. Hung GBK, Cheung HK A survey of in-patient and outpatient antipsychotic prescriptions in Hong Kong. Psychol Bull. 2008 ; 32: 103-105.
12. Meagher D., Moran M. Sub-optimal prescribing in an adult community mental health service: prevalence and determinants. Psychol Bull. 2003 ; 27: 266-270.
13. Harrington M., Lelliot P., Paton C., Okocha C., Duffett R., Sensky T. The results of a multicentre audit of the prescribing of antipsychotic drugs for in-patients in the UK. Psychol Bull. 2002 ; 26: 414-418.
14. Safer DJ, Magno Zito J., DosReis S. Concomitant psychotropic medication for youths. Am J Psychiatry. 2003 ; 160: 438-449.
15. Janssen B., Weinmann S., Berger M., Gaebel W. Validation of polypharmacy process measures in in-patient schizophrenia care. Shizophr Bull. 2004 ; 30: 1023-1033.
16. Shader RI, Greenblatt DJ Use of benzodiazepines in anxiety disorders. N Engl J Med. 1993 ; 328: 1398-1405.
17. Woods JH, Winger G. Current benzodiazepine issues. Psychopharmacology. 1995 ; 118: 107-115.
18. Ballenger JC Long-term pharmacologic treatment of panic disorder. J Clin Psychol. 1991 ; 52 (suppl 12). 18-23.
19. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry. 1994 ; 151 (suppl 12). 1-35.
20. Department of Health and Children (Republic of Ireland). Report of the Benzodiazepine Committee. Dublin, Ireland: Government Publications ; 2002.
21. National Institute for Clinical Excellence. Guidance on the Use of Zaleplon, Zolpidem and Zopiclone for the Short-term Management of Insomnia. Technology Appraisal Guidance 77. London, UK: National Institute for Clinical Excellence ; 2004.
22. National Institute for Clinical Excellence. Anxiety: Management of Anxiety (Panic Disorder, With or Without Agoraphobia, and Generalised Anxiety Disorder) in Adults in Primary, Secondary and Community Care. Clinical Guideline 22 (amended). London, UK: National Institute for Clinical Excellence ; 2007.
23. Royal College of Psychiatrists. Consensus Statement on High-Dose Antipsychotic Medication. Council Report CR138. London, UK: Royal College of Psychiatrists ; 2006.
24. Shiloh R., Zemishlany Z., Aizenberg D., et al. Sulpiride augmentation in people with schizophernia partially responsive to clozapine: a double-blind, placebo-controlled study. Br J Psychol. 1997 ; 171: 569-573.
25. British national formulary. London, UK: BMJ group and RPS publishing ; 2008.
26. Tyson PJ, Mortimer AM, Wheeler JA High-dose antipsychotic treatment in clinical practice: a review, audit and survey of consultant psychiatrist opinions. Psychol Bull. 1999 ; 23: 661-664.
27. National Institute for Clinical Excellence. Guidance on the Use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia. Technology Appraisal Guidance, No. 43. London, UK: National Institute for Clinical Excellence ; 2002.
28. Ray WA, Chung CP, Murray KT, Hall K., Stein CM Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009 ; 360 (3). 225-235.
29. Waddington JL, Youssef HA, Kinsella A. Mortality in schizoprenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10 year prospective study. British J of Psych. 1998 ; 173: 325-329.